Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
B-cell Leukemia: early-phase trial registry
2 of 4 indexed B-cell Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
B-cell Leukemia: 4 US clinical trials tracked, 2 recruiting.
B-cell Leukemia is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Pharmacyclics, running 1 of these trials.
Enrollment posture brief
Registry condition b-cell-leukemia
OPEN 2 | RECR 50% | LATE 0 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
B-cell Leukemia lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for B-cell Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
B-cell Leukemia is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Arkansas Children's Hospital Research Institute
NCT07422337
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT05442515
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Seattle Children's Hospital
NCT01683279
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
Pharmacyclics
NCT00849654
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on B-cell Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on B-cell Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this B-cell Leukemia page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 B-cell Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pharmacyclics sponsors the most B-cell Leukemia trials on record, review their full trial history before evaluating a specific study. See Pharmacyclics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This B-cell Leukemia condition card totals 4 registered trials; most-linked intervention PCI-32765; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.